Country, sex, edss change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome

C Meyniel; T Spelman; VG Jokubaitis; M Trojano; G Izquierdo; F Grand'Maison; C Oreja-Guevara; C Boz; A Lugaresi; M Girard; P Grammond; G Iuliano; M Fiol; JA Cabrera-Gomez; R Fernandez-Bolanos; G Giuliani; J Lechner-Scott; E Cristiano; J Herbert; T Petkovska-Boskova; R Bergamaschi; V van Pesch; F Moore; N Vella; M Slee; V Santiago; M Barnett; E Havrdova; C Young; CA Sirbu; M Tanner; M Rutherford; H Butzkueven; D Paolicelli; G Lucchese; P Iaffaldano; M Marriott; T Kilpatrick; J King; A Van der Walt; J Haartsen; O Skibina; C Zwanikken; G De Luca; V Di Tommaso; D Travaglini; E Pietrolongo; M di Ioia; D Farina; P Duquette; T Petersen; R Hupperts; J Correale; C Ysrraelit; E Cartechini; E Pucci; D Williams; L Dark; F Verhuel; M Vella; ML Saladino; M Paine; C Shaw

Journal article

Country, sex, edss change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome

C Meyniel, T Spelman, VG Jokubaitis, M Trojano, G Izquierdo, F Grand'Maison, C Oreja-Guevara, C Boz, A Lugaresi, M Girard, P Grammond, G Iuliano, M Fiol, JA Cabrera-Gomez, R Fernandez-Bolanos, G Giuliani, J Lechner-Scott, E Cristiano, J Herbert, T Petkovska-Boskova Show all

Plos One | PUBLIC LIBRARY SCIENCE | Published : 2012

DOI: 10.1371/journal.pone.0038661

Download PDF

Abstract

Objectives: We conducted a prospective study, MSBASIS, to assess factors leading to first treatment discontinuation in patients with a clinically isolated syndrome (CIS) and early relapsing-remitting multiple sclerosis (RRMS). Methods: The MSBASIS Study, conducted by MSBase Study Group members, enrols patients seen from CIS onset, reporting baseline demographics, cerebral magnetic resonance imaging (MRI) features and Expanded Disability Status Scale (EDSS) scores. Follow-up visits report relapses, EDSS scores, and the start and end dates of MS-specific therapies. We performed a multivariable survival analysis to determine factors within this dataset that predict first treatment discontinuati..

View full abstract

University of Melbourne Researchers

Timothy Spelman Author

Trevor Kilpatrick Author

Related Projects (1)

CENTRE FOR TRANSLATIONAL NEUROSCIENCE: A MODULAR PLATFORM FOR TRANSLATING DISCOVERY INTO HEALTH OUTCOMES

Clinical Centre of Research Excellence in Translational Neuroscience will provide people, pathways and resources to create a novel platform ..

Grants

Awarded by National Science Foundation

Funding Acknowledgements

This study was funded by the MSBase Foundation. CM is supported by the Journees de Neurologie de Langue Francaise. HB is supported by National Health and Medical Research Council (NHMRC) Career Development Fellowship 628856, the work was supported by NHMRC Australia grant 1032484. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Research Grants: The following authors have received research grants from Bayer Schering: AL, RB & MB; Biogen Dompe: AL & RB; Biogen Idec: MT, FGM, PG & MB; Merck Serono MT, AL, RB & MB; Novartis: MT, FGM, AL, RB & MB; Sanofi Aventis: AL, PG, RB & MB; Teva: FGM & MB. Travel Grants: The following authors have received travel grants from Bayer Schering: AL, VvP & CAS; Biogen Dompe: AL; Biogen Idec: MG, VvP, NV, CY & HB; EMD Serono: MG; Merck Serono: AL, VvP & CY; Novartis: TS, AL, VvP, NV & HB; Sanofi Aventis: AL, VvP & HB; Teva: AL, CY & CAS. Honoraria: The following authors have received honoraria from Bayer Schering: MT, GIz, AL, PG, JLS, JH, RB & MB; Biogen Dompe: AL & RB; Biogen Idec: MT, GIz, MG, PG, JLS, JH, VvP & MB; EMD Serono: MG, PG & FM; Merck Serono: MT, GIz, AL, JLS, JH, RB, & MB; Novartis: GIz, AL, MG, PG, JLS, RB, NV & MB; Sanofi Aventis: MT, GIz, AL, JLS, RB & MB; Teva: GIz, FGM, AL, MG, PG, JH, MB & CAS. Advisory Board Membership: The following authors report sitting on advisory boards for Bayer Schering: COG, AL, MS & CY; Biogen Dompe: AL; Biogen Idec: COG, MG, VvP, MS, CY & HB; Merck Serono: COG, AL, MS & CY; Novartis: FGM, COG, MS, CY & HB; Sanofi Aventis: MS & HB; Teva: COG, MG & CY. FGM also reports receiving research grants from EMD Serono, Genzyme, ONO & UBC. COG has participated in clinical trials and other research projects promoted by Biogen-Idec, GSK, Teva & Novartis. AL has received travel and research grants from the Associazione Italiana Sclerosi Multipla and is a Consultant of "Fondazione Cesare Serono". FM has participated in MS clinical trials sponsored by EMD Serono and Bayer. NV has received travel support from Eisai & GSK. EH acknowledges financial support from the Czech Ministry of Education (research program MSM 0021620849). CY reports sitting on the scientific advisory board of Lilly. CY participates in clinical trials sponsored by Biogen Idec, Merck Serono, Novartis, Roche, Sanofi Aventis, and Teva. CY holds research grants from the MS Society United Kingdom, the MND association United Kingdom and the British Polio Fellowship. CY is on the steering committee for LiCALS. HB serves on steering committees for trials conducted by Merck Serono, Biogen Idec and Novartis. HB has received research support from Merck Serono, Novartis and Biogen Idec in his capacity as honorary chair of the MSBase Foundation. HB is the recipient of an National Health and Medical Research Council (NHMRC) Career Development Award (628856), NHMRC Project Grants (566513, 628799, 1009757), NHMRC Centre of Excellence Award (1001216), an ARC Linkage Grant (LP110100473)RG & a National MS Society (United States of America) Project Grant (RG3850A3/1). These disclosures do not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials. There are no patents, products in development or marketed products to declare.